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Background and rationale 
Currently about 1 million Australians were diagnosed with diabetes.1 Most (85%) of those had 
type 2 diabetes (T2DM).1  Local and international data suggest that about one-third to half of 
those with diabetes was undiagnosed.2-4 More than half of the population in Australia is 
overweight and obese, which puts them at higher risk of T2DM. Diabetes is associated with a 
wide range of macrovascular and microvascular complications including blindness, 
amputations, renal disease, and cardiovascular diseases. Currently A$1507 million or 2.3% of 
the health budget was spent on diabetes.5 It is projected that by 2033 T2DM will pose an 
economic burden of A$8 billion, with a 436% increase in projected expenditure compared to 
2002-3.6 This projected increase was driven by demographic factors, increase in obesity 
prevalence, extra services per case, and currently untreated diabetes.6  
GDM is defined as any degree of glucose intolerance with onset or first diagnosis during 
pregnancy.7 About 10-13% of all pregnancies in Australia are complicated by GDM.8 
Pregnancies with GDM are more likely to have adverse outcomes including macrosomia, 
perinatal mortality, preeclampsia and caesarean delivery.9 Offsprings born to mothers with 
GDM are also at increased risk of obesity, abnormal glucose metabolism and cardiovascular 
diseases later in life.10 About 30-84% of GDM patients re-develop the condition in subsequent 
pregnancies.11. One of the most significant long-term health impacts of GDM is the significantly 
increased risk of developing diabetes. The greatest increase in the incidence of type 2 diabetes 
following GDM occurs within the first five years, with up to 50% of women with prior GDM 
developing T2DM within this timeframe.11. As a young, at-risk group for T2DM, women with 
prior GDM represent a great opportunity for public health intervention in T2DM prevention.  
In many cases T2DM is a preventable disease. Studies have consistently shown that dietary 
modification along with moderate physical activity reduces the incidence of diabetes in high-risk 
populations.12, 13 Lifestyle intervention has also been shown to reduce the development of 
diabetes in women who had GDM (averaging 12 years from index pregnancy) by 50%.14  
A well-timed lifestyle intervention program for women post-GDM that includes determination of 
individual risk of developing Type 2 Diabetes, setting priorities, problem solving and goal 
setting for lifestyle modification to reduce the likelihood of progression to T2DM, has the 
potential to positively change the longer term health of these women and their children.  
HISTORY OF DIABETES PREVENTION IN 
AUSTRALIA  
The Australian Government funded the Greater Green Triangle Diabetes Prevention Program 
(GGT DPP) to study the effectiveness and feasibility of identification of those at high risk, and a 
six-session group intervention in primary care. From waist circumference changes, it is 
estimated that the GGT DPP reduced the risk of developing diabetes by 40% and 
cardiovascular disease by 16%.13 The results of this Project were used to inform the National 
Chronic Disease Strategy resulting in the recommendation of diabetes prevention to the 
Council of Australian Governments in 2007. Victoria has led the way with the Life! Program, 
group based intervention based on GGT DPP. The NHMRC-funded Melbourne Diabetes 
Prevention Study has demonstrated the effectiveness and cost-effectiveness of the Life! 
program.15 
In 2012, the NHMRC-funded Mothers After Gestational Diabetes in Australia (MAGDA) Study 
evaluated a group-based intervention for post-GDM women, but found that there were barriers 
to attendance at the intervention such as childcare and travel. As it was delivered in a group 
setting, it was difficult to address individual needs such as tailoring for cultural differences.  
Telephone-based interventions have been shown to be effective in producing and maintaining 
lifestyle changes.16 The Australia's Get Healthy Information and Coaching Service® launched 
by the New South Wales government in 2009 provided telephone coaching services which 
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resulted in significant improvements in body weight, waist circumference, fruits and vegetable 
intake, and physical activity.17 A more recent telephone-delivered lifestyle intervention targeting 
Australian primary care patients with Type 2 Diabetes also demonstrated effectiveness in 
weight loss and increase in physical activity.18 This new delivery mode may suit postpartum 
mothers as it addresses some of the barriers to lifestyle intervention such as need for childcare 
and lack of time. 19 Delivering lifestyle intervention via telephone could also be more cost-
effective.20  
 
Study design 
The TeleMAGDA pilot is a single-arm implementation trial with no randomization and no 
controls.  Up to 35 participants will be recruited in Victoria and South Australia via the National 
Gestational Diabetes Register and through existing consented women in the MAGDA study 
control arm.   
 
The objectives of this pilot are to determine: 
 The feasibility of delivering a telephone-based lifestyle intervention  for postpartum 
women with a history of gestational diabetes 
 The participation/attrition rate of the intervention. 
 The acceptability of telephone-based MAGDA among postpartum mothers  
 
Methods 
SELECTION AND RECRUI TMENT  
Recruitment 
Participants will be recruited from the following sources: 
 The MAGDA Study: Women from MAGDA NDSS NGDR mail-out who live too far away 
from MAGDA groups, MAGDA control participants who have completed their 
involvement, MAGDA participants who were ineligible for T1, MAGDA women in the 
intervention group but who have not been able to join any of the groups offered to them. 
All women approached will have already consented to future contact through the 
MAGDA study. Potential participants will be contacted by telephone by a research staff 
member. 
 NDSS/NGDR mail out: A letter and a teleMAGDA information brochure (with contact 
details for the study) will be sent out to women registered with the National Gestational 
Diabetes Register and living in the Colac area.  
 A supplementary form of recruitment will also be used. An invitation to participate 
webpage will be added to the MAGDA study website, which has been set up to support 
a national survey of women with GDM and their GPs. The invitation to participate will 
include a copy of the plain language statement on the page and participants will be able 
to express their interest in being contacted by research team for a thorough explanation 
through filling in their contact details onto the page’s “contact us” section 
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Inclusion and exclusion criteria 
Inclusion criteria:  
 Diagnosed GDM in the last pregnancy (Fasting glucose ≥ 5.5mmol/L or 2-h glucose ≥ 
8.0 mmol/L on a 75g OGTT) or a GCT ≥12.0mmol/L. 
 Post natal OGTT does not show T2DM (Fasting glucose ≥ 7.0mmol/L or 2-h glucose 
≥11.1mmol/L) 
 Residing in Victoria or South Australia 
 ≥3 months and less than/equal to 24 months post-partum 
 
Exclusion criteria: 
 Established  diabetes (T1DM or T2DM) 
 Cancer (not in remission) 
 Severe mental illness in the last three months 
 Substance abuse (illicit drugs) in the last three months 
 Myocardial infarction in the last three months 
 Difficulty with English 
 Pregnant at any time during the study (from baseline  to follow up data collection) 
 Surgical or medical intervention to treat obesity 
 
Screening procedures 
If the woman is interested in the study, the teleMAGDA Recruiter will screen for eligibility.  If 
eligible, the recruiter will review the teleMAGDA consent form with the participant; if still 
interested, the woman will be posted a Plain Language Statement and Consent Form along 
with a reply paid envelope and asked to complete and return the consent form. 
The teleMAGDA recruiter will address the following: 
 Ask participant what motivated them to respond 
 Find out their antenatal and postnatal OGTT results 
 Describe the program—what it involves, tests, commitment 
 Describe the research 
 Obtain verbal consent (signed consent) 
 Go through eligibility criteria 
 Post them a PLSCF, instructions for baseline testing, clinical test form and 
questionnaires 
If ineligible, no further contact will be made with the woman. If the consent form is not received 
within one week, the TeleMAGDA Recruiter will contact the woman.    
Second Screening: 
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 If the woman does not have recent OGTT results (post-natal, within last 6-months), she 
will be asked to contact her GP and have one done in order to exclude T2DM and 
commence participation in the study. 
 
 
 
Fig 1:  Recruitment Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REPORTING  
The TeleMAGDA trial will be reported according to the CONSORT (Consolidated Standards of 
Reporting Trials) 2010 Statement (see link). 
http://www.consort-statement.org 
STUDY INTERVENTION  
Theoretical framework 
The theoretical framework of this intervention is based on the Health Action Process Approach 
(HAPA) and self-regulation theory.21,22 Several other theories, strategies and constructs are 
incorporated into the design of the intervention. These include the social learning theory, 23,24 
empowerment-oriented counseling,25-27 goal-setting approach, 28, 29 self-efficacy and self-
evaluation.22, 30 
The HAPA model was developed by Ralph Schwarzer.  This information has been taken from: 
http://www.hapa-model.de/. 
The Health Action Process Approach (HAPA) suggests that the adoption, initiation, and 
maintenance of health behaviours must be explicitly conceived as a process that consists of at 
One/two methods of recruitment will be employed. 
If eligible, Recruiter will provide/send the 
woman PICF, questionnaires and Data 
Collection pack with prepaid envelope  
Not interested. Ask why? 
Recruiter will contact the woman to provide more 
information & answer questions 
Not eligible. No further contact  
Participant attends Baseline data 
collection (T1) 
If interested. Check eligibility 
Recruiter asks questions on 
diabetes status, cancer, 
severe mental illness, 
substance abuse, myocardial 
infarction, proficiency in 
English, Antenatal and 
postnatal OGTT results. 
No further 
contact  
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least a motivation phase and a volition phase. The latter might be further subdivided into a 
planning phase, action phase, and maintenance phase. It is claimed that perceived self-efficacy 
plays a crucial role at all stages along with other cognitions (Bandura, 1997). For example, risk 
perceptions serve predominantly to set the stage for a contemplation process early in the 
motivation phase but do not extend beyond. Similarly, outcome expectancies are chiefly 
important in the motivation phase when individuals balance the pros and cons of certain 
consequences of behaviours, but she lose her predictive power after a personal decision has 
been made. However, if one does not believe in one's capability to perform a desired action, 
one will fail to adopt, initiate and maintain it.  
The Motivation Phase  
In the motivation phase, the individual forms an intention to either adopt a precaution measure 
or change risk behaviours in favour of other behaviours. Self-efficacy and outcome 
expectancies are seen as the major predictors of intentions. Most previous models treat these 
two as being unrelated predictors. However, there might be a temporal and causal order 
among her. Outcome expectancies can be seen as precursors of self-efficacy because people 
usually make assumptions about the possible consequences of behaviours before inquiring 
whether she can really take the action herself. If self-efficacy is specified as a mediator 
between outcome expectancies and intention, the direct influence of outcome expectancy on 
intention may dissipate. But the research findings on this issue are very inconsistent, rendering 
both cognitions primary candidates for motivating change. Under conditions where individuals 
have no experience with the behaviour she is contemplating, we assume that outcome 
expectancies may have a stronger direct influence than self-efficacy. Only after a sufficient 
level of experience is attained does self-efficacy become more influential in forming an 
intention.  
The influential role of risk perception (or threat) in the motivation and volition process may have 
been overestimated in past research and interventions. Fear appeals are of limited value; 
rather, the message has to be framed in a way that allows individuals to draw on her coping 
resources and to exercise skills in order to control health threats. In persuasive 
communications, a focus should be made on self-percepts of personal coping capabilities to 
manage effective precaution strategies. This suggests a causal order where threat is specified 
as a distal antecedent that helps to stimulate outcome expectancies which further stimulate 
self-efficacy. A minimum level of threat or concern must exist before people start contemplating 
the benefits of possible actions and ruminate her competence to actually perform her. The 
direct path from threat to intention may become negligible if expectancies are already well 
established.  
In establishing a rank order among the three direct paths that lead to intention, it is assumed 
that self-efficacy and outcome expectancies dominate, whereas threat (or risk perceptions) 
may fail to contribute any additional direct influence. As indirect factors, however, threat may be 
of considerable significance within the motivation phase. The particular context and one's 
personal experience play a role and may change the pattern of weights.  
The Volition Phase  
It is common knowledge that good intentions do not necessarily guarantee corresponding 
actions. Correlations between intentions and behaviours vary tremendously. While in the 
motivation phase it is described what people choose to do, in the subsequent action or volition 
phase it is described how hard she try and how long she persist. The right-hand part of Figure 
1 consists of three levels: cognitive, behavioural, and situational. The focus is on cognitions 
that instigate and control the action, i.e., a volitional or self-regulative process which is 
subdivided into action plans and action control.  
When a preference for a particular health behaviour has been shaped, the intention has to be 
transformed into detailed instructions of how to perform the desired action. If, for example, 
someone intends to lose weight, it has to be planned how to do it, i.e., what foods to buy, when 
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and how often to eat which amounts, when and where to exercise, and maybe even whether to 
give up smoking as well. Thus, a global intention can be specified by a set of subordinate 
intentions and action plans that contain proximal goals and algorithms of action sequences. 
The volition process is hardly influenced by outcome expectancies, but more strongly by self -
efficacy, since the number and quality of action plans are dependent on one's perceived 
competence and experience. Self-efficacy beliefs influence the cognitive construction of 
specific action plans, for example, by visualizing scenarios that may guide goal attainment. 
These post-decisional pre-actional cognitions are necessary because otherwise the person 
would act impulsively in a trial-and-error fashion and would not know where to allocate the 
available resources.  
Once an action has been initiated, it has to be controlled by cognitions in order to be 
maintained. The action has to be protected from being interrupted and abandoned prematurely 
due to incompatible competing intentions which may become dominant while a behaviour is 
being performed. Meta-cognitive activity is needed to complete the primary action and to 
suppress distracting secondary action tendencies. Daily physical exercise, for example, 
requires self-regulatory processes in order to secure effort and persistence and to keep other 
motivational tendencies at a distance (such as the desire to eat, socialize, or sleep) until these 
tendencies can prevail for a limited time period.  
When an action is being performed, self-efficacy determines the amount of effort invested and 
the perseverance. People with self-doubts are more inclined to anticipate failure scenarios, 
worry about possible performance deficiencies, and abort her attempts prematurely. People 
with an optimistic sense of self-efficacy, however, visualize success scenarios that guide the 
action and let her persevere in face of obstacles. When running into unforeseen difficulties she 
quickly recover.  
Performing an intended health behaviour is an action, just as is refraining from a risk behaviour. 
The suppression of health-detrimental actions requires effort and persistence as well, and 
therefore is also guided by a volitional process that includes action plans and action control. If 
one intends to quit smoking or drinking, one has to plan how to do it. For example, it is 
important to avoid high-risk situations where the pressures to relapse are overwhelming. 
Attaining proximal subgoals helps increase the difficulty level of situations until one can resist 
under all possible circumstances. If someone is craving a cigarette or a drink, action control 
helps him or her to survive the critical situation. For example, individuals can make favourable 
social comparisons, refer to her self-concept, or simply pull herself together. The more these 
meta-cognitive skills and internal coping dialogues are developed and the better she is 
matched to specific risk situations, the easier the urges can be controlled. Self-efficacy helps to 
re-establish the perseverant efforts needed for the accomplishment of self-imposed goals.  
Finally, situational barriers as well as opportunities have to be considered. If situational cues 
are overwhelming, meta-cognitive skills fail to protect the individual and the temptation cannot 
be resisted. Actions are not only a function of intentions and cognitive control, but are also 
influenced by the perceived and the actual environment. A social network, for example, that 
ignores the coping process of a quitter by smoking in his presence, creates a difficult stress 
situation which taxes the quitter's volitional strength. If, on the other hand, a spouse decides to 
quit too, then a social support situation is created that enables the quitter to remain abstinent in 
spite of lower levels of volitional strength.  
In sum, the action phase can be described along three levels: cognitive, behavioural, and 
situational. The cognitive level refers to self-regulatory processes that mediate between the 
intentions and the actions. This volitional process contains action plans and action control and 
is strongly influenced by perceived self-efficacy, but also by perceived situational barriers and 
support. 
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Materials 
Participant Handbook 
This is a self-help manual for the participants. It provides information on the study as well as 
introduces the intervention goals along with strategies to achieve them. This material helps to 
keep the telephone session short and manageable (20-30 mins), while still building the same 
range of skills in the participants as they would receive in a 2-hour in-person session. Each 
chapter consists of a series of short articles which are developed specifically to engage 
postpartum women. The articles describe the significance of the intervention goals to their 
health and provide the knowledge required to achieve that goal e.g. types of fat and fibre and 
their food sources, the science of energy balance, the concept of energy density, portion sizes, 
glycemic index, the amount of fibre, fat and energy in common food items, the amount of sleep 
a baby needs, sleep-training techniques, ways to relieve stress, identifying anxiety and 
depression etc.  
Practical tips are included throughout the manual to address the physical, mental, emotional 
and social needs of postpartum women, e.g. having a high-fibre breakfast with protein to keep 
the energy up, making baby and toddler-friendly family meals, finding time to eat instead of 
multitasking, make and freeze baby-friendly meals, not to worry about competing baby’s 
developmental milestones with other mums, making time to do something fun with partner etc. 
Skills required for lifestyle modification are also included in the manual e.g. ingredients 
substitution, recipe modification, food label reading, choosing healthy take-away choices etc. 
These skills are reinforced through homework and activities at the end of each chapter (see 
example in Fig 3. 
Fig 3. An example of homework in the TeleMAGDA Participant’s Manual   
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The participant will read a chapter and complete the homework and activities at the end of the 
chapterin preparation for the upcoming session .  
 
During the telephone session, the coach will refer to the Participant Handbook to address any 
knowledge gap and to go through the answers for the homework with the participants. 
The content of the Participant Handbook is as follow: 
 Ready, set go! 
 How to use this manual 
 First session: Why am I doing this? 
 Chapter A: How do celebrities lose their baby weight 
 Chapter B: Why Eskimos don’t have heart attacks 
 Chapter C: How Disney princesses keep their figure 
 Chapter D: Why cows don’t get diabetes 
 Chapter E: A beautiful mind 
 Last session: Planning for the long haul 
 Tracking tools 
 Additional facts 
 
Coach Manual 
This is a manual for the coaches. It provides an overview of the study and the intervention 
sessions. It describes the structure of calls and ways to facilitate goal-setting and problem-
solving (see excerpt below). Suggested scripts for the telephone sessions are also included in 
the manual. Homework and other important points of discussion are included. The section on 
Session Guides provides an outline of each telephone session on a single page for the coach 
to refer to during the telephone session.  
 
Below is an excerpt from the Facilitators Manual on goal setting: 
FACILITATING A SMART ER GOAL-
SETTING SESSION 
Review goal 
Use open questions to ask the participant what the goal she set at the last 
session and how well that has gone. Write down her previous goal on the 
participant casebook. Acknowledge ANY progress she made, and how 
difficult it can be to make these changes. Once she has described her 
success in her own words, ask her to summarize her success on a 5 point 
scale (5-achieved goal completely, 1-did not achieve at all, 3-achieved about 
half of the goal) and note this beside her goal. Using open questions, if she 
managed or nearly managed her goal, ask her what the biggest barrier she 
encountered was. 
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The content of the Coach Manual is as follow: 
 Acknowledgements 
 About TeleMAGDA 
 About this manual 
 Program timeline 
 Basic structure of calls (after the first session) 
 Effective communication 
 What is a SMARTER goal 
 Facilitating a SMARTER goal-setting session 
 Tracking tools 
 Phone session 1 
 Chapter A: Exercise 
 Chapter B: Fat and saturated fat 
 Chapter C: Weight management 
 Chapter D: Fibre 
 Chapter E: Sleep, stress and depression 
 Last session: Rewards and Lapses 
 Appendix 
 Session guides 
 
Participant Casebook 
This is a data tracking instrument to be filled in by the coaches. It collects process data such as 
the attempts of calls, time and duration of calls. It also record personal information on the 
participants such as their perceived risks, previous goals, perceived barriers etc, which helps 
the coach to provide continuous ‘care’ to the participants. The content of the Participant 
Casebook is as follow: 
 Appointment schedule 
 Consents 
 Personal information 
 Outcome measurements (T1) 
 Phone session 1 
 Phone session 2 
 Phone session 3 
 Phone session 4 
 Phone session 5 
 Phone session 6 
 Phone session 7  
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 Outcome measurements (T2) 
 Notes 
Delivery 
The intervention will be administrated by trained health care professionals. All facilitators will 
be provided with a manual and a one-day training by an experienced researcher in telephone-
based intervention.  . 
The training will include: 
 Motivational interviewing skills 
 Effective communication skills 
 Goal setting and problem solving 
 Role-play of the telephone sessions 
 
After Baseline results and questionnaires have been received by the Research Assistant, the 
participant will be posted a participant handbook. Participants will be involved in the study for 3 
months. The intervention group will be asked to complete a series of seven sessions. All the 
sessions will be carried out at two week intervals (apart from where public and other holidays 
interrupt the sequence of sessions). If participant availability is a problem the sessions will be 
conducted no more than 4 weeks apart. Each telephone session will run for approximately 30 
minutes. 
Intervention goals 
There have been successful implementation trials for diabetes prevention in Finland31 and 
Australia.13 Evidence-based goals used in the GGT Life! Program, Melbourne Diabetes 
Prevention Study and Mothers After Gestational Diabetes in Australia (MAGDA) Study are 
used this study: 
1. Reduce fat intake (no more than 30% of energy from fat) 
2. Decrease saturated fat intake (no more than 10% of energy from saturated fat) 
3. Increase fibre intake (at least 15g/1000Kcal per day) 
4. Increase physical activity (at least 30 minutes of moderate exercise per day) 
5. Reduce body weight (at least 5% of body weight reduction within 12 months)  
Intervention topics 
The first session is about establishing the participants’ reasons to be in the program and 
addressing their risk perception. The last session is about maintaining the changes in the long 
term. Sessions 2 to 6 introduces the five intervention goals for diabetes prevention. The 
intervention goals can be delivered in any order, depending on the participant’s choice. 
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Table 1: An example of TeleMAGDA session topics 
Session Content 
Session 1 
 
Establishing why she wants to be in the program 
Her risks of developing diabetes 
Introduction to the TeleMAGDA goals 
Setting a physical activity goal 
Session 2  
 
Fat and saturated fat 
Review and set physical activity and healthy eating goals 
 
Session 3  
 
Weight Management 
Review and set physical activity and healthy eating goals 
Session 4  
 
Fibre 
Review and set physical activity and healthy eating goals 
Session 5  Exercise 
Review and set physical activity and healthy eating goals 
 
Session 6  
 
Sleep, stress and depression 
Review and set physical activity and healthy eating goals 
Set goals on sleep, stress and/or depression 
 
Session 7 
 
Lapses and relapses, rewards 
Long term goal setting 
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Adherence assessment  
Participant completion of each telephone session will be recorded and a continuous analysis 
kept. Program completers defined as those women who completed 5 or more telephone 
sessions. Note what has been achieved from the 5 goals from changes over length of program 
in study questionnaire data. 
STUDY PROCEDURES  
Data collection 
Table 2: Schedule for data collection 
Assessment Screening 1 
(Before 
recruited into 
the study) 
Between 
Screening 1 
and Baseline 
testing 
Baseline (T1) 
postpartum 
(Screening 3) 
 
After last 
phone 
coaching 
session (T2) 
Informed Consent 
 
 
 x   
Results of antenatal 
and postnatal OGTT 
 x   
Capillary Fasting 
Glucose 
 
  x x 
Anthropometric 
Measurements 
(height, weight, waist, 
hip) 
  x x 
BP   x x 
Demographics   x  
Health Status   x x 
Food Frequency 
Questionnaire 
  x x 
The Active Australian  
Questionnaire 
  x x 
Quality of Life (AQOL-
8D) 
  x x 
Risk Perception   x x 
Psychological 
wellbeing (PHQ9) 
  x x 
Social Support 
(Multidimensional 
Scale of Perceived 
Social Support) 
  x x 
Exclusion Criteria x  x x 
  
 
Footer text is 9pt Arial. 
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Baseline assessments (Time 1)  
 Fasting Capillary Blood Glucose reading using Glucometer (Finger Prick) 
 Anthropometric measurements  
o Height 
o Weight 
o Waist Circumference 
o Hip Circumference 
 Blood Pressure 
 Questionnaires 
o Demographics 
o Health Status 
o Food Frequency Questionnaire 
o Risk Perception Questionnaire 
o Quality of Life (AQOL-8D) 
o The Active Australian Questionnaire 
o Psychological Health (PHQ9) 
o Social Support (Multidimensional Scale of Perceived Social Support) 
Completion/Final data collection (Time 2) 
After the final telephone session  
 
 Fasting Capillary Blood Glucose reading using Glucometer (Finger Prick) 
 Anthropometric measurements  
o Height 
o Weight  
o Waist Circumference 
o Hip Circumference 
 Blood Pressure 
 Questionnaires 
o Demographics 
o Health Status 
o Food Frequency Questionnaire 
o Risk Perception Questionnaire 
o Quality of Life (AQOL-8D) 
o The Active Australian Questionnaire 
o Psychological Health (PHQ9) 
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o Social Support (Multidimensional Scale of Perceived Social Support) 
  
Data collection will be conducted by the participant’s GP. The participants recruited in the 
Colac area, via the mail out, will be required to attend their local pharmacy for data 
collection. 
Participants will have options for questionnaire completion: 
 Paper copy, with included reply paid post envelope 
 Email web surveys link 
 Via the MAGDA website 
Feasibility and attendance data 
A log of the following data will be recorded for each participant: 
 Estimated number and % of the target population with GDM 
 Estimated number of eligible participants based on inclusion/exclusion criteria  
 List the reasons for and number of exclusions by the investigators or program.  
 List the number of "lost or indeterminate cases" - e.g., wrong information, not able to 
be contacted, moved, no answer.  
 Actual number exposed to recruitment  
 Actual number who respond to recruitment 
 List reasons for declining participation   
 Actual number who are eligible 
 List number and reasons for ineligibility  
 Actual number who started  
 List number and reasons pre-commencement attrition 
 Compare demographics of those who participated and those who didn’t 
 Record how many ____ and when (what week of the intervention) _____ subjects 
dropped from the study. 
 An exit survey will be conducted with all participants following their completion of the 
study, including those who withdraw 
 Compare differences between those completing and those not completing the study 
on adverse events, illness status, sociodemographics, geography, baseline scores 
on dependent variables, and other key variables. 
Cost 
The following will be collected and used as a measure of cost of delivering the intervention: 
 Intervention materials 
 Equipment 
 Personnel 
 Time 
 Space 
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 Number of missed calls, completed calls, rescheduled calls, call duration, topics 
covered, goals reviewed, setting new goals. 
 Type of method used for questionnaire completion 
 Effectiveness of pharmacy in data collection 
 
SAFETY ASSESSMENT  
Risk management process 
The process of risk management for TeleMAGDA will follow the path set out in the diagram 
below. 
Fig 3:  Risk management process 
 
 
Source: Standards Australia International & Standards New Zealand (2001) Guidelines for 
Managing Risk in the Healthcare Sector: Australian/New Zealand Handbook. Sydney: 
Standards Australia International; p. 21, Figure 3. 
Specification of Safety Parameters 
If measurements are taken by pharmacist, a feedback letter will be sent to the participants 
GP.  
Adverse events and serious adverse events 
Adverse events  
 Needle stick injury to participant or study staff, use of lancet 
 
Serious adverse events  
 Injury sustained by the mother and / or infant (or accompanying child(ren)) either 
while in transit to / from the Data Collection sessions or while participating in the 
Testing sessions. 
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Reporting procedures for adverse events 
A primary role of the Project Management Group will be to monitor and review the adverse 
events through its monthly meetings. The Board will be kept informed on a quarterly basis of 
any adverse events. NHMRC and involved HRECs will be informed as required. 
Follow-up for adverse events 
Standard operating procedure for research personnel, Data Collectors (GPs or pharmacists) 
and Facilitators will outline steps to be taken in the event of either an adverse event or a 
serious adverse event.  In the event that an adverse event does occur the risk management 
process, as outlined in Figure 2 above, will be followed immediately.  The adverse event will 
be reported to the Project Board. 
Safety Monitoring  
The TeleMAGDA study will follow the NHMRC Australian Health Ethics Committee (AHEC) 
position statement: Monitoring and reporting of safety for clinical trials involving therapeutic 
products (2009). 
Monitoring and reporting of safety for clinical trials involving therapeutic products guidelines 
can be viewed here: 
http://www.nhmrc.gov.au/_files_nhmrc/file/health_ethics/hrecs/reference/090609_nhmrc_positio
n_statement.pdf  
James Dunbar (CIA) will oversee the whole project with support from all site-specific 
investigators in order to ensure that risk management processes are implemented. 
Intervention discontinuation 
If the woman develops cancer, severe mental illness, experiences a heart attack or stroke, 
becomes pregnant or commences another lifestyle intervention which impacts on primary 
outcome measures during the study period, the woman may be withdrawn from the study if 
she is unable to continue or it is inappropriate for her to continue her involvement.   Each 
case will be evaluated by the Protocol Violation Committee. 
 
DATA COLLECTION  
Data collection forms 
Online and paper based forms will be used to collect information. The clinical measurements 
will be recorded by the GP/pharmacist, with all other questionnaires containing self-report 
information. The only identifying information will be the participant ID which is located on the 
front of each form/questionnaire, with the exception of the patient demographic 
questionnaire SECTION A-1 which contains participants’ contact details.  
Data collection forms used by the GP (containing only ID codes) will be 
posted/faxed/emailed/MMS to Research Assistant at Deakin Burwood.  
Participant will have the option of completing either the web based survey (either via email 
link or the MAGDA website) or paper copy. Any paper questionnaires will be posted back by 
participant in provided envelopes (with identifiable documentation sent in an Express post 
envelope and non-identifiable documentation sent in standard post). These data will be 
collected by the Research Team and transferred to locked cabinets at Burwood site 
(Melbourne).  
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Web-based surveys 
The Health Surveys service run by the Faculty of Health, Deakin University, has the 
endorsement of the University Solicitor’s office, the Faculty Research Ethics Group 
(HEAGH) and the University Human Research Ethics Group (DUHREC) for its use in high-
risk research. 
The process which governs this service requires a single point of contact, called the User 
(normally the CI, always a University Employee, in this case the DPP-PM) who has sole 
access to the data once exported to the share. 
In all instances, the strongest recommendation is made that the User collect only data which 
is not identifiable within the survey instrument, and the issuing of ID codes is handled 
entirely within the research team, with the Health Surveys Contact never able to access this 
information as a safeguard for respondents’ privacy and anonymity. This has been strictly 
adhered to in the case of the MAGDA study. 
All data are stored on Deakin University eSolutions servers, which are ISO 9000 compliant 
for data security and access and quality control. 
During the survey data collection period, only the person in charge of running the service is 
able to access the data, and is legally and ethically bound by the rules of the University and 
the Grant-issuing body, as defined in the aforementioned Health Surveys process map. 
At the end of the data collection period, the Health Surveys contact exports all reports and 
data, as well as a full backup of all pilot and final survey instruments (with results) to the 
Specified Share, which is created early in the process, accessible only by the User, and is 
read-only to safeguard the data in its unmodified state. The User alone is then responsible 
for copying the data to a suitable Deakin University share for analysis and dissemination 
within the research team. Once the User has accepted custodianship of the data, all records 
of the survey instruments and respondent data are permanently removed from the Health 
Surveys server, and remain only in the Specified Share. 
Data management 
Data collected from women at baseline and as soon as possible after the last group session 
are sent back to office in Burwood via post, email, fax or MMS by the data collectors 
(GPs/pharmacists). 
Questionnaires are either completed directly online via Deakin health surveys or posted 
back to office in Burwood by participant (with identifiable documentation sent in an Express 
post envelope and non-identifiable documentation sent in standard post). These 
questionnaires are checked for accuracy and completeness by the Research Assistant on to 
ensure there is no missing data, any missing fields will be clarified with participant over 
phone to confirm intentional omission. 
 
QUALITY ASSURANCE  
Data Collection 
The Data Collection Forms will contain easy to read instructions about performing data 
collection alongside required measurements. 
Training 
Training will be provided for the facilitators. The training will include  
 Practical facilitation skill development activities, including: 
o Engaging the mothers 
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o Effective communication 
o Goal setting 
o Problem solving 
 Rehearsal of telephone sessions 
 Facilitators may be observed delivering sessions of the program by a trained 
observer in order to ensure fidelity of session delivery or sessions may be audio 
recorded for audit purposes using a uni-directional microphone.  Recordings will be 
stored securely on USB memory sticks in the research office.  Recordings may be 
coded using validated tools and the recordings would then be deleted as per the 
TeleMAGDA Facilitator’s Quality Assurance Framework. 
 
PROTOCOL DEVIATIONS  
Any protocol deviations will be registered on the Protocol Exception Register and discussed 
at regular Protocol Exception Meetings with a clinical Chief Investigator, Associate 
Investigator and the TeleMAGDA Project Manager.  
 
The TeleMAGDA Project Management group will meet regularly to monitor the progress of 
the overall intervention across all sites, with particular responsibility for risk management. 
 
TIMELINE  
30th June 2015 
 Literature review completed 
 Study protocol finalized  
 Study materials (coaching and participant handbooks) designed and printed 
 Ethics approvals received from each jurisdiction 
 Participants recruited (n=35) and consented 
 Baseline data collected from all participants 
 Negotiations with national telephone health coaching providers underway for 
partnership in major study 
 
31st December 2015 
 All participant data collected, cleaned and analyzed 
 Preliminary publication of findings submitted 
 Policy brief presented to Victorian Department of Health and SA Health 
 Knowledge translation symposium hosted to highlight lessons learned from MAGDA 
and teleMAGDA studies 
 Draft NHMRC application submitted for peer review 
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Results 
Findings from the pilot will be available by the end of 2015. Main outcomes are: 
 Acceptability 
 Feasibility  
 Participation rate  
 Barriers to participation (reasons for non-participation) 
 Attrition rate 
 
Discussion 
Results from the pilot study will be available by the end of 2015. 
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